Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | SAT1 | P21673 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719539 | 0.95 | CYP2C19 (0.39) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL17784254 | 0.90 | LMNA (0.31) | LMNA | |
| SCHEMBL1195517 | 0.87 | LMNA (0.32) | LMNA | |
| SCHEMBL12972154 | 0.86 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL12677849 | 0.83 | PAOX (0.40) | CYP2C19CYP1A2TSHRLMNA | |
| SCHEMBL57093 | 0.81 | CYP2C19 (0.48) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL14454275 | 0.81 | LMNA (0.35) | CYP2C19MEN1GLAKMT2ATSHR | |
| SCHEMBL6382948 | 0.79 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL12190484 | 0.79 | CA12 (0.50) | CYP2C19MEN1KMT2ACYP1A2TSHR | |
| SCHEMBL1071877 | 0.79 | TSHR (0.46) | CYP2C19MEN1GLAKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7905927-B2 | Method for lightening and/or coloring human keratin fibers using a composition comprising an aminotrialkoxy silane or aminotrialkenyloxy silane compound and device | L'OREAL, SA (FR) | 2011-03-15 | — | — | US | disclosed |
| US-20100303748-A1 | METHOD FOR LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING A COMPOSITION COMPRISING AN AMINOTRIALKOXY SILANE OR AMINOTRIALKENYLOXY SILANE COMPOUND AND DEVICE | L'OREAL S.A. (FR) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303748-A1 | METHOD FOR LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING A COMPOSITION COMPRISING AN AMINOTRIALKOXY SILANE OR AMINOTRIALKENYLOXY SILANE COMPOUND AND DEVICE | KRT18, FABP4, APMAP | CYP2C19 3938/4885MEN1 4698/4885GLA 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.